collecting system were noted. The indications for stenting are uncontrolled hypertension, worsening of renal function, and progression of stenosis. Primary outcomes of this study were to assess survival rate, percentage of restenosis, and graft loss. Secondary outcomes were to analyze the reduction of BP, graft function, and number of antihypertensive medications.
rEsults
Among 526 renal allograft recipients, seven patients had TRAS (1.3%). The native kidney disease was known in three patients (focal segmental glomerulosclerosis: 1, diabetic nephropathy: 1, IgA nephropathy: 1). Out of 7 patients, four (57%) were males. Six of the seven renal transplant recipients are from deceased donors. Six patients presented with allograft dysfunction, three patients presented with refractory hypertension, and three patients presented with anuria. All donor kidneys had single renal artery anastomosed in end-to-end fashion to internal iliac artery. The timeline of TRAS ranged from 3 to 30 months (median: 5 months) postrenal transplant. Screening Doppler showed significant hemodynamic changes in all patients and intervention done in all cases.
Statistical analysis
We performed a paired two-sample Student's t-test to compare pre-and post-operative levels of serum creatinine and BP and estimated glomerular filtration rate (eGFR). The number of antihypertensive medications was compared with the use of Wilcoxon rank test. P = 0.05 was considered the threshold of statistical significance.
General demographics and laboratory parameters are shown in Tables 1 and 2. The mean PSV of transplant renal artery by Doppler USG was 245 ± 20 cm/s. All patients had significant stenosis at anastomotic site; all were treated with percutaneous transluminal angioplasty (PTA) with stenting, and one patient had recurrent TRAS due to in-stent restenosis and treated with balloon angioplasty and stenting. The efficacy of stenting in our study is suggested by decrease in mean systolic and diastolic BP, serum creatinine, and number of BP medications.
The mean serum creatinine [ Figure 1 ] decreased from preprocedure value of 2.18 mg% to 1.6 mg% at 4 weeks and 1.4 mg% at 8 weeks (P < 0.05). The mean eGFR (MDRD formula) [ Figure 2 ] increased from preprocedure value of 39.7 ml/min to 63.5 ml/min at 4 weeks (P < 0.05). The mean number of antihypertensive drug [ Figure 3 ] requirement reduced from 2.5 to 2 drugs after 4 weeks postprocedure (P value not significant). Calcium channel blockers, alpha blocker, diuretics, and angiotensin-converting enzyme (ACE) inhibitors are used. Three patients were on ACE inhibitor during diagnosis. The average systolic BP [ Figure 4 ] at presentation was 168.5 mmHg and it reduced to 140 mmHg after 4 weeks postprocedure (P < 0.05). The average diastolic BP [ Figure 5 ] reduced from 101 to 91 mmHg after surgical intervention (P value not significant).
Out of seven patients, three patients have normal graft function (42.8%), three had chronic graft dysfunction (42.8%), and one patient had graft loss (14.2%). Two patients had pseudoaneurysm at puncture site at femoral artery which was managed conservatively, and one patient had restenosis. About 85.7% of the patients were deceased donor transplant recipients. Graft survival rate following intervention was 86%.
discussion
TRAS is an increasingly recognized, potentially reversible complication of kidney transplantation. TRAS may be a consequence of faulty surgical technique, arterial damage during donor nephrectomy or kidney perfusion, kinking and compression of the renal artery, size discrepancy between donor and recipient renal arteries, and atherosclerosis of the donor or recipient renal arteries. [5, 6] Risk factors for TRAS include acute rejection episodes, cytomegalovirus infection, prolonged cold ischemia time, and progression of recipient atherosclerosis. [7] [8] [9] The reported incidence of TRAS in different series ranged from 1% to 12%. The incidence of TRAS in our study was 1.3%. In an Indian study by Avinash et al., the incidence of TRAS was found to be 5.06%. PTA/stenting was done in all patients with technical success of 100%, and clinical success was 79.2% at 6 months. [10] The most common presentation of TRAS are new-onset or refractory hypertension, graft dysfunction, or even acute renal failure because of overzealous diuretic therapy or addition of ACE or angiotensin receptor blocker to the antihypertensive treatment. Renal hypoperfusion activates renin-angiotensin system with resulting fluid retention, edema, cardiac failure, and recurrent pulmonary edema. Doppler ultrasonography (DUS) is commonly used as a screening tool in the initial evaluation. DUS has many advantages; it is noninvasive, inexpensive, has good sensitivity (87%-94%) and specificity (86%-100%), can evaluate hemodynamic significance, grading, and localization of stenosis, and can assess revascularization. [11] Screening Doppler showed significant hemodynamic changes in all the patients in our study. Angiography is the gold standard for TRAS and provides a roadmap that is helpful in planning treatment procedure. The treatment modality differs depending on the severity of stenosis. The patient can be managed conservatively with low-dose ACE inhibitor if the stenosis is not hemodynamically significant with cautious monitoring of serum creatinine and potassium level. TRAS should be monitored by Doppler at least every 6 months for progression of stenosis. Hemodynamically significant stenosis is treated with PTA with or without stenting. PTA is minimally invasive procedure with success rate around 70%-90%. [12] The success rate of PTA in our study was 85.7%. One patient had recurrent TRAS after 1 year due to in-stent restenosis at anastomotic site and treated with balloon angioplasty and stenting with successful restoration of graft function. In a largest Indian series, 43 patients with TRAS had been reported by Sriram et al.; only 11 patients with significant stenosis were intervened with significant increase in GFR and BP control after intervention, [13] [ Figure 6 ] and rest of them managed conservatively. Surgical reconstruction of the transplant renal artery is indicated when the restenosis is at the same anastomotic site, kinks, failed PTA, and recurrent lesions. [14] Early diagnosis is crucial for successful restoration of graft function and to prevent complications. conclusion 1. The incidence of TRAS in the study was 1.3% 2. About 85.7% of the patients were deceased donor transplant recipients 
